Last reviewed · How we verify
ASA plus Clopidogrel
ASA and clopidogrel together inhibit platelet aggregation through different pathways to reduce thrombotic events.
ASA and clopidogrel together inhibit platelet aggregation through different pathways to reduce thrombotic events. Used for Acute coronary syndrome, Percutaneous coronary intervention with stent placement, Secondary prevention of myocardial infarction.
At a glance
| Generic name | ASA plus Clopidogrel |
|---|---|
| Sponsor | Texas Cardiac Arrhythmia Research Foundation |
| Drug class | Dual antiplatelet agent |
| Target | COX-1 (aspirin); P2Y12 receptor (clopidogrel) |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | FDA-approved |
Mechanism of action
Aspirin irreversibly inhibits cyclooxygenase (COX), blocking thromboxane A2 production and platelet activation. Clopidogrel is a P2Y12 receptor antagonist that prevents ADP-induced platelet aggregation. Combined, they provide dual antiplatelet therapy with complementary mechanisms to prevent stent thrombosis and recurrent cardiovascular events.
Approved indications
- Acute coronary syndrome
- Prevention of stent thrombosis after percutaneous coronary intervention
- Secondary prevention of myocardial infarction and stroke
Common side effects
- Bleeding (major and minor)
- Dyspepsia
- Gastrointestinal hemorrhage
- Intracranial hemorrhage
- Rash
Key clinical trials
- The Effect and Safety of Combined Anti-platelet Treatment in Acute Ischemic Stroke Due to Large Artery Atherosclerosis (PHASE4)
- Short-Term Anticoagulation Versus Antiplatelet Therapy for Preventing Device Thrombosis Following Left Atrial Appendage Closure (PHASE4)
- Randomized Clinical Trial of Endovascular Recanalization for Symptomatic Non-Acute Intracranial Artery Occlusion（REPAIR） (NA)
- Clopidogrel vs. Aspirin for Cardiovascular Risk Reduction in Patients With S. Aureus Bacteremia (PHASE4)
- Precision Reperfusion Therapy for Disabling Minor Stroke With Large Vessel Occlusion Beyond Time Window (PHASE3)
- SIMPLAAFY Clinical Trial (NA)
- Combination Antithrombotic Treatment for Prevention of Recurrent Ischemic Stroke in IntraCranial Atherosclerotic diseaSe (CATIS- ICAS) (PHASE3)
- STrategies for Antithrombotic tReatment Following Transcatheter Edge-to-Edge Repair in Patients Without an Indication for Oral Anticoagulant (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- ASA plus Clopidogrel CI brief — competitive landscape report
- ASA plus Clopidogrel updates RSS · CI watch RSS
- Texas Cardiac Arrhythmia Research Foundation portfolio CI